argenx company profile
Company profile
argenx has 1,863 employees and is headquartered in Amsterdam, Netherlands.
With revenue of $4.2 billion, argenx SE is a commercial-stage biopharmaceutical company that develops therapies for autoimmune diseases. It offers VYVGART for generalized myasthenia gravis and immune thrombocytopenia, and VYVGART HYTRULO for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. Its development programs cover a range of other autoimmune conditions, and it has partnerships and license agreements with Zai Lab, Halozyme Therapeutics, OncoVerity and AbbVie. The United States accounted for 83.2% of revenue, with the remainder coming from Japan, China and the rest of the world.
In the fiscal year ended December 2025, revenue rose 88.4% to $4.2 billion and net income reached $1.3 billion. The company had 1,863 employees. It was incorporated in 2008 and is headquartered in Amsterdam, the Netherlands. Its shares also trade on Euronext Brussels.
Company facts
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Headquarters
- Laarderhoogtweg 25, 1101 EB, Amsterdam
- Employees
- 1,863
- Chief executive
- Karen Massey
- Founded
- 2008
- Fiscal year
- January - December
- Listing
- ARGX · NASDAQ
- Currency
- USD
- ISIN
- US04016X1019
- Website
- argenx.com
argenx and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| argenxARGX | United States | $60.37B | 1,863 | 31.9% | 33.3 |
| BeOne MedicinesONC | United States | $47.58B | 12,000 | 17.8% | 53.4 |
| ModernaMRNA | United States | $90.38B | 4,700 | -80.8% | — |
| Royalty PharmaRPRX | United States | $39.85B | 100 | 64.4% | 45.3 |
| Revolution MedicinesRVMD | United States | $37.27B | 883 | -853.0% | — |
| Regeneron PharmaceuticalsREGN | United States | $98.84B | 15,410 | 30.4% | 21.1 |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
